Q-omics provides the consensus-scored ELOCP27 profile across patient tissues and cancer cell-line models. ELOCP27 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, ELOCP27 is differentially expressed in 4, with the highest sampling consensus in UCEC. Additionally, ELOCP27 RNA expression shows 5,630 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight OV, and UCEC as cancer lineages where ELOCP27 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ELOCP27 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ELOCP27 survival associations across molecular data types. ELOCP27 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ELOCP27 RNA expression–survival associations across cancer types. High ELOCP27 expression shows unfavorable associations in COAD, KIRP and PAAD, but favorable associations in OV, LGG and HNSC. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify OV as the clearest survival context for ELOCP27 RNA expression.
This table summarizes ELOCP27 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for ELOCP27. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ELOCP27 shows higher tumor expression in UCEC, LUAD, COAD and ESCA. The UCEC box plot shows higher ELOCP27 RNA expression in tumor versus normal tissue (log2 FC = +0.387, t-test p = .003).
This table shows molecular features associated with ELOCP27 in patient tissues and cancer cell lines. In patient samples, ELOCP27 shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
